JunHe, Osborne Clarke and Proskauer Rose has advised European plasma products producer Grifols on the control of 26.2 percent stake in A-share listed company Shanghai RAAS, with Grandway Law Offices advising the seller.
The transaction value is about $1.87 billion and in exchange, Shanghai RAAS has gained 45 percent non-majority share in Grifols’ subsidiary, Grifols Diagnostic Solutions (GDS). This is by far the largest M&A deal in the blood products industry globally.
Established in 1909, Grifols is a global healthcare company that focuses on producing plasma-derived medicines and transfusion medicine. Bioscience, diagnostic, hospital and bio supplies are their core business.
The JunHe team was led by partners Jiang Chen and Xudong Tao, while the Grandway team was led by partners Guan Wang, Dapeng Li and Shi Tang.